• First Berlin ended analyst coverage of Marinomed Biotech on Sept. 24, citing the company’s insolvency-driven shutdown.
• Marinomed sought court-administered restructuring on July 22, following missed milestone payments expected from Unither Pharmaceuticals.
• Insolvency administrator Dr. Ulla Reisch moved to close operations; the court accepted the motion and ordered the business closure.
• Asset sales are set to begin under the insolvency process, according to the research update.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marinomed Biotech AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26898) on September 24, 2026, and is solely responsible for the information contained therein.